1. Hepa Wash collaborates with GALS program
Hepa Wash announced in a Dec. 7 press release that it has collaborated with the German Accelerator Life Sciences (GALS) program to expand its company into the U.S. Hepa Wash recently introduced an Advanced Organ Support (ADVOS) procedure that offers multi-organ support for liver, lungs and kidneys while correcting acid-base balance disorders.
2. FDA clears Camber Spine interbody device
Camber Spine has received FDA 510(k) clearance for its Spira-C Open Matrix Cervical Interbody device, according to a Dec. 7 press release. The Spira-C Open Matrix Cervical Interbody is an interbody fusion implant that enhances fusion. It is the second implant clearance of the company and is a 3D printed titanium implant. It supplies the optimal environment for cell proliferation and bone growth.
3. NanoVibronix inks U.K. distribution deal
NanoVibronix announced in a Dec. 5 press release that it has entered a distribution agreement with BHR Pharmaceuticals to distribute its PainShield in the U.K. PainShield is an alternative to opioids for pain relief following surgery. It is an ultrasound-based product that is designed to treat pain in nerves, muscles, joints and soft tissue using localized ultrasound that heals soft tissue.
4. FDA clears CoLink ‘see-through’ plating system from In2Bones
In2Bones has received FDA clearance for an addition to its CoLink Forefoot Bone Plating System, according to a Dec. 5 press release. The bone plating system is used to stabilize bones during the post-surgical healing process. It features titanium metal and PEEK with an X-ray transparent PEEK hub that lets the surgeon watch a patient’s bone heal.
5. Stimwave receives 510(k) clearance
Stimwave announced in a Nov. 28 press release that it has received 510(k) clearance for its SandShark Injectable Anchor System. The clearance allows for clinicians to insert Stimwave’s Wireless Pain Relief technology in minimally-invasive outpatient procedures to treat chronic pain. The SandShark enables clinicians to anchor electrodes while causing the least amount of tissue damage to treat patients with stimulation and no opioids.
